4503N Stock Chart & Stats
$253.00
$0.00(0.00%)
At close: 4:00 PM EDT
$253.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$204.11 - $281.91
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$470.11B
Enterprise Value$4.25M
Total Cash (Recent Filing)$244.70B
Total Debt (Recent Filing)$589.87B
Price to Earnings (P/E)11.6
Beta-0.05
Next Earnings
Nov 04, 2026EPS Estimate
6.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)203.70
Shares Outstanding1,809,663,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.46
Price to Sales (P/S)2.11
P/FCF Ratio8.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$261.37Price Target Upside3.31% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)21.41
Revenue Forecast (FY)$246.67B
Bulls Say, Bears Say
Bulls Say
Robust Free Cash Flow GenerationTTM operating cash flow (~¥598B) and free cash flow (~¥540B) show durable cash conversion. FCF runs at ~0.90x net income, supporting sustained R&D, dividends, and strategic investments without relying solely on new financing, bolstering long-term financial flexibility.
High Margins And Operating ProfitabilityConsistently high gross and operating margins reflect product pricing power and manufacturing scale across therapeutic areas. Strong EBIT/EBITDA margins provide durable internal funding for pipeline work and commercial investment, helping sustain competitive positioning over the medium term.
Strategic Pipeline Expansion Via Sangamo BidPursuing Sangamo's Fabry program is a structural move to bolster rare-disease capabilities. Adding an orphan program can extend exclusivity windows and diversify revenue drivers, strengthening long-term growth potential and reducing reliance on existing product lifecycles.
Bears Say
Historical Net Margin VolatilityLarge swings in net margin indicate earnings have been materially affected by one-offs, product-mix shifts, or cyclical items. This reduces predictability of core profitability and complicates planning for R&D and capital allocation over the next several quarters.
Meaningful Leverage Swings HistoricallyWide swings in debt-to-equity signal inconsistent capital structure and past reliance on variable financing. Such variability can limit strategic optionality, increase refinancing risk in adverse conditions, and suggests capital allocation has not been steady across cycles.
Operating Cash Flow Low Vs RevenueOCF covering only ~46% of revenue suggests working-capital intensity or timing gaps between sales and cash collection. If this persists, it could constrain funding for organic growth or acquisitions without tapping liquidity, increasing sensitivity to cash-cycle stress.
Astellas Pharma News
4503N FAQ
What was Astellas Pharma Inc’s price range in the past 12 months?
Astellas Pharma Inc lowest stock price was $204.11 and its highest was $281.91 in the past 12 months.
What is Astellas Pharma Inc’s market cap?
Astellas Pharma Inc’s market cap is $470.11B.
When is Astellas Pharma Inc’s upcoming earnings report date?
Astellas Pharma Inc’s upcoming earnings report date is Nov 04, 2026 which is in 57 days.
How were Astellas Pharma Inc’s earnings last quarter?
Astellas Pharma Inc released its earnings results on Aug 05, 2026. The company reported $8.423 earnings per share for the quarter, beating the consensus estimate of $5.757 by $2.665.
Is Astellas Pharma Inc overvalued?
According to Wall Street analysts Astellas Pharma Inc’s price is currently Undervalued.
Does Astellas Pharma Inc pay dividends?
Astellas Pharma Inc does not currently pay dividends.
What is Astellas Pharma Inc’s EPS estimate?
Astellas Pharma Inc’s EPS estimate is 6.61.
How many shares outstanding does Astellas Pharma Inc have?
Astellas Pharma Inc has 1,809,663,100 shares outstanding.
What happened to Astellas Pharma Inc’s price movement after its last earnings report?
Astellas Pharma Inc reported an EPS of $8.423 in its last earnings report, beating expectations of $5.757. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astellas Pharma Inc?
Currently, no hedge funds are holding shares in MX:4503N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astellas Pharma Inc
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
4503N Company Deck
4503N Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.View all MX:4503N earnings summaries4503N Stock 12 Month Forecast
Average Price Target
$261.37
▲(3.31% Upside)